Erratum: Editor's note: Regulation of OSU-03012 toxicity by ER stress proteins and ER stress–inducing drugs (American Association for Cancer Research Inc (2014) 13 (2384–2398) DOI: 10.1158/1535-7163.MCT-14-0172);Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2384-2398

  Booth, Laurence ^a   Roberts, Jane L ^a   Cruickshanks, Nichola ^a   Grant, Steven ^b   Poklepovic, Andrew ^b   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; AUTOPHAGY PROTEIN 5; BECLIN 1; BETA6 INTEGRIN; CASPASE 8; CD133 ANTIGEN; CD15 ANTIGEN; CD36 ANTIGEN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HERMES ANTIGEN; JANUS KINASE; MICROTUBULE ASSOCIATED PROTEIN 2; N(G) NITROARGININE METHYL ESTER; PROTEIN; PROTEIN BCL XL; SILDENAFIL; TRANSCRIPTION FACTOR SOX2; CARBOLINE DERIVATIVE; DNA BINDING PROTEIN; ERN1 PROTEIN, HUMAN; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; REGULATORY FACTOR X TRANSCRIPTION FACTORS; RIBONUCLEASE; SULFONAMIDE; TADALAFIL; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA; HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING; CANCER STEM CELL; DRUG EFFECTS; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; METABOLISM; NEURAL STEM CELL; PATHOLOGY; TUMOR CELL CULTURE;

CARBOLINES; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDOPLASMIC RETICULUM STRESS; ENDORIBONUCLEASES; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PURINES; PYRAZOLES; SULFONAMIDES; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84922653008     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-19-0666     Document Type: Erratum

References (58)

1. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble JW, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.
2. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S,Mone A, et al. A novel celecoxib derivative, OSU-03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase-and Bcl-2-independent mechanism. Blood 2005;105:2504-9.
3. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004;31:12-21.
4. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005;11:8213-21.
5. Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 2006;15:7-13.
6. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice BMC Cancer 2006;12:6-9.
7. Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 2005;33:724-7.
8. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006;66:257-65.
9. Patel MI, Subbaramaiah K, Du B, Chang M, Newman RA, Cordon-Cardo C, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
10. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
11. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006;70:589-603.
12. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008;73:1168-84.
13. Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, et al. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol Ther 2012;13:224-36.
14. Mateo J, De Bono SJ, Ramanathan RK, Lustberg MB, Zivi A, Basset D, et al. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2013;31: (suppl; abstr 2608). Available from: http://meetinglibrary.asco.org/content/115148-132
15. Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther 2012;13:1501-11.
16. Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol 2013;23:547-55.
17. Pavitt GD, Ron D. New insights into translational regulation in the endoplasmic reticulum unfolded protein response. Cold Spring Harb Perspect Biol 2012;4. pii: a012278.
18. Hollien J, Weissman JS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 2006;313:104-7.
19. Hollien J, Lin JH, Li H, Stevens N, Walter P, Weissman JS. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol 2009;186:323-31.
20. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013;1833:3460-70.
21. Bork P, Sander C. A hybrid protein kinase-RNase in an interferon-induced pathway? FEBS Lett 1993;334:149-52.
22. Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, et al. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol 2014;85:408-19.
23. Booth L, Roberts JL,Conley A, Cruickshanks N, Ridder T, Grant S, et al. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biol Ther 2014;15:305-16.
24. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005;7:164-76.
25. Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, et al. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther 2013;14:982-96.
26. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 2010;107:18202-7.
27. Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 2005;4:257-70.
28. Kato H, Katoh R, Kitamura M. Dual regulation of cadmium-induced apoptosis bymTORC1 through selective induction of IRE1 branches in unfolded protein response. PLoS ONE 2013;8:e64344.
29. Kato H, Nakajima S, Saito Y, Takahashi S, Katoh R, Kitamura M. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ 2012;19:310-20.
30. Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol 2012;81:527-40.
31. Sentelle RD, Senkal CE, Jiang W, Ponnusamy S, Gencer S, Selvam SP, et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol 2012;8:831-8.
32. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
33. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail 2012;5:79-86.
34. Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res 2012;43:470-5.
35. Zhang X, Yan G, Ji J, Wu J, Sun X, Shen J, et al. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem 2012;113:2738-43.
36. Kato M, Blanton R,WangGR, Judson TJ, Abe Y, Myoishi M, et al. Direct binding and regulation of RhoA by cyclic GMP-dependent protein kinase Ia. J Biol Chem 2012;287:41342-51.
37. Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal 2011;23:1921-6.
38. Friebe A, Koesling D. The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. Nitric Oxide 2009;21:149-56.
39. Komalavilas P, Shah PK, Jo H, Lincoln TM. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMPdependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 1999;274:34301-9.
40. Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 2008;283:29572-85.
41. Choi CY, Park KR, Lee JH, Jeon YJ, Liu KH, Oh S, et al. Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by down-regulation of NF-kappaB, ERK1/2, and p38 kinase. Eur J Pharmacol 2007;576:151-9.
42. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, et al. Exisulind induction of apoptosis involves guanosine 30,50-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-42.
43. Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 2004;64:3966-73.
44. Zhu B, Strada S, Stevens T. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005;289:L196-206.
45. Zhu B, Zhang L, Alexeyev M, Alvarez DF, Strada SJ, Stevens T. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am J Physiol Lung Cell Mol Physiol 2009;296:L220-8.
46. Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 2007;7:437-54.
47. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003;101:265-9.
48. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008;1230:290-302.
49. Zhu B,Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 2005;94:336-50.
50. Ha KS, KimKM, Kwon YG, Bai SK, Nam WD, Yoo YM, et al. Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J 2003;17:1036-47.
51. Hayden MA, Lange PA, Nakayama DK. Nitric oxide and cyclic guanosine monophosphate stimulate apoptosis via activation of the Fas- FasL pathway. J Surg Res 2001;101:183-9.
52. Reinehr R, Görg B, Höngen A, Häussinger D. CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes. J Biol Chem 2004;279:10364-73.
53. Mannick JB, Miao XQ, Stamler JS. Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem 1997;272:24125-8.
54. Dimmeler S, Haendeler J, Sause A, Zeiher AM. Nitric oxide inhibits APO-1/Fas-mediated cell death. Cell Growth Differ 1998;9:415-22.
55. Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, et al. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 1996;27:823-6.
56. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010;70:6313-24.
57. De Nadai C, Sestili P, Cantoni O, Lièvremont JP, Sciorati C, Barsacchi R, et al. Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. Proc Natl Acad Sci U S A 2000;97:5480-5.
58. Rabkin SW. Fumonisin blunts nitric oxide-induced and nitroprusside-induced cardiomyocyte death. Nitric Oxide 2002;7:229-35.